Marketing GLP-1, Peptide, and Compounded Therapeutics Practices: Understanding the Regulatory Landscape
Listen to Article
Part 1: Introduction
Overview of the regulatory landscape facing GLP-1, peptide, and compounded therapeutics marketing
If you are marketing physician-directed practices that offer GLP-1 medications, peptide protocols, or compounded treatments — whether you are the physician, the clinic owner, or the marketing professional driving patient acquisition — you need to understand the federal regulatory landscape you are operating in. It is far more dangerous than most people in this space realize.
The growth of weight-management programs, longevity medicine, and telehealth-based prescribing models has created enormous business opportunity. But that same growth has attracted the attention of every major federal enforcement agency in healthcare: the Department of Justice, HHS Office of Inspector General, the FDA, and the Federal Trade Commission. In jurisdictions like the Southern District of Florida, enforcement activity in healthcare fraud matters has been substantial for years — and it is accelerating.
Federal and state regulatory agencies — including DOJ, HHS-OIG, FDA, and FTC — are actively pursuing enforcement actions involving healthcare marketing representations, referral arrangements, compounded pharmaceutical claims, and prescribing practices. Marketing professionals and consultants working with therapeutic practices face exposure alongside the physicians and clinic owners they serve. The government prosecutes the entire ecosystem, not just the provider.
The explosive growth of GLP-1, peptide, and compounded therapeutic marketing has drawn focused attention from federal enforcement agencies. Marketing claims, compensation structures, and business model design are all under scrutiny.
The GLP-1 and Peptide Boom Meets Federal Oversight
The expansion of physician-directed medical practices offering advanced therapeutics has been nothing short of explosive. GLP-1 medications, peptide therapy protocols, hormone replacement programs, and compounded weight-management treatments have created a multi-billion-dollar industry that continues to grow.
Innovation in medical treatment is not inherently problematic. Many physician-directed practices operate within appropriate legal and ethical boundaries. The exposure arises when medical services intersect with reimbursement systems, compounded pharmaceuticals, and direct-to-consumer marketing — and that intersection is where the vast majority of practices in this space now operate.
The regulatory risk is not about the medicine itself — it is about how the business is structured and how services are marketed. Compensation arrangements, advertising claims, prescribing models, and referral relationships are the primary triggers for federal enforcement in the advanced therapeutics space.
The pace of growth in GLP-1 and peptide therapeutics has outstripped the compliance infrastructure at most practices. That gap between growth and compliance is precisely where federal investigators focus their attention.
Compounded Medications and the FDA Framework
Compounded medications — including certain GLP-1 formulations and peptide therapies — are not FDA-approved in the same manner as commercially manufactured drugs. This distinction is not academic. It is the foundation of a regulatory framework that creates significant criminal exposure when violated.
Compounding is permitted under specific statutory frameworks, typically requiring patient-specific prescriptions and preparation by properly licensed pharmacies or outsourcing facilities operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. When marketing materials imply equivalence to FDA-approved brand medications — semaglutide marketed as interchangeable with Ozempic or Wegovy, for example — federal agencies take notice immediately.
The FDA has expressed direct concern about misleading marketing in this space, particularly when compounded products are presented in ways that blur the distinction between compounded formulations and approved pharmaceuticals. When those marketing claims are paired with volume-driven business models, the combination creates a regulatory perfect storm.
Marketing Representations That Trigger Investigation
Advertising carries independent regulatory implications that most marketing professionals in this space dramatically underestimate. The FTC and FDA have overlapping jurisdiction over healthcare marketing claims, and both agencies have been increasingly aggressive in pursuing enforcement.
Marketing that exaggerates efficacy — promising specific weight-loss numbers, guaranteed outcomes, or transformative results — violates FTC standards for truthful advertising and can trigger FDA enforcement if claims relate to drug efficacy. Marketing that implies FDA approval or regulatory endorsement where none exists creates exposure under both FDA regulations and state consumer protection laws. Marketing that uses patient testimonials or before-and-after imagery without adequate substantiation and disclosure can constitute deceptive trade practices.
Every marketing claim about a compounded therapeutic should be reviewed against three questions: Is this claim substantiated by adequate evidence? Does this claim imply FDA approval or equivalence where none exists? Could this claim be interpreted as a guarantee of specific medical outcomes? If the answer to any of these is yes, the claim needs to be revised before publication.
In recent years, enforcement efforts have focused not only on providers but also on the broader ecosystem of marketing agencies, telehealth coordination companies, and revenue operations teams supporting medical services. If you are generating leads, creating advertising copy, or managing patient acquisition for a practice in this space, your exposure is real and personal.
Business Model Structures That Draw Scrutiny
Beyond marketing claims, the structure of the business model itself is often the primary focus of federal investigation. Compensation arrangements tied to prescription volume, patient acquisition, or revenue percentages raise serious compliance questions — particularly when federal healthcare programs are implicated at any point in the payment chain.
Revenue-sharing models where marketing partners receive a percentage of revenue generated by patients they refer. Per-patient fees where lead generators or patient acquisition companies are compensated for each patient who converts to treatment. Commission-based structures where sales representatives are compensated based on the volume of treatments or prescriptions generated.
Even where a practice does not bill Medicare or Medicaid directly, regulators may examine financial relationships across the entire network to determine whether improper incentives influenced prescribing decisions. The Anti-Kickback Statute reaches any arrangement where remuneration is exchanged for referrals of patients covered by federal healthcare programs — and the government interprets that reach broadly.
Telemedicine-Based Prescribing: The Enforcement Hotspot
Telemedicine-based prescribing models have become a particular enforcement priority for federal authorities. The combination of remote patient evaluation, high-volume prescribing, and revenue-driven business models creates a concentration of exposure that prosecutors find deeply attractive.
Cases across the country have examined whether adequate medical evaluation occurred prior to prescribing, whether the physician had a legitimate doctor-patient relationship, and whether business structures incentivized medically unnecessary prescriptions. While telehealth is a legitimate and valuable tool, regulators assess whether operational safeguards were in place to ensure compliance — or whether the telehealth model was designed primarily as a prescribing funnel.
Federal prosecutors in telemedicine fraud cases focus on three critical questions: Did a legitimate medical evaluation occur before prescribing? Was the prescribing decision driven by medical necessity or by business incentives? Were adequate safeguards in place to ensure clinical independence from the revenue model? If the answer to any of these questions suggests that the business model drove prescribing rather than clinical judgment, criminal exposure is significant.
The penalties for telemedicine fraud mirror those for traditional healthcare fraud — conspiracy charges carrying up to 10 years per count, wire fraud charges carrying up to 20 years per count, and Anti-Kickback Statute violations carrying up to 10 years per count. When multiple counts are stacked in a single indictment, the sentencing exposure becomes staggering.
The Anti-Kickback Statute and Referral Compensation
The federal Anti-Kickback Statute — 42 U.S.C. § 1320a-7b(b) — is the primary weapon federal prosecutors use against compensation structures that incentivize patient referrals. Understanding this statute is essential for anyone involved in marketing or business development for therapeutic practices.
The statute prohibits knowingly and willfully offering, paying, soliciting, or receiving anything of value to induce or reward referrals of patients for services covered by federal healthcare programs. The "anything of value" standard is extraordinarily broad — it covers cash payments, percentage-based compensation, free services, meals, entertainment, and virtually any other form of remuneration.
Safe harbor exceptions exist but are narrow, and they require strict compliance with specific conditions. Most marketing arrangements in the advanced therapeutics space do not fit neatly within existing safe harbors — which means they require careful structuring and ongoing compliance monitoring.
What Marketing Professionals Need to Know
For marketing professionals and consultants working with physician-directed practices in the GLP-1, peptide, and compounded therapeutics space, the risk exposure is direct and personal. The government does not limit its prosecution to the physician who signed prescriptions or the clinic owner who designed the business model. Everyone who participated in the scheme — including the people who created the marketing, generated the leads, and designed the patient acquisition funnel — faces potential criminal liability.
Risk mitigation for marketing professionals begins with compensation structure. Flat-fee arrangements that are not tied to patient volume or revenue present the lowest compliance risk. Clear documentation that marketing activities are separated from clinical decision-making provides a defensible record. All therapeutic claims should be accurate, substantiated, and reviewed for compliance before publication. If you are being compensated based on the number of patients you bring in or the revenue those patients generate, you are in the danger zone.
"Innovation in medicine is not the problem. The problem is when growth outpaces compliance and business models create incentives that regulators view as fraud. Understanding that distinction before launching your next campaign is not optional — it is survival."— Aaron M. Cohen, Principal Attorney
Compliance as Competitive Advantage
None of this suggests that practices offering GLP-1 medications, peptides, or compounded therapeutics are inherently improper. The medical services themselves can be legitimate, valuable, and life-changing for patients. What this reflects is the reality that the intersection of healthcare, reimbursement, and advertising operates within a heavily regulated framework — and operating outside that framework carries consequences that can destroy careers, businesses, and lives.
Operators and consultants who approach compliance proactively will find that it is not just a defensive measure — it is a competitive advantage. Practices that can demonstrate robust compliance programs, properly structured compensation arrangements, and substantiated marketing claims are better positioned to survive enforcement scrutiny, attract quality referral partners, and build sustainable businesses.
Awareness of enforcement trends, thoughtful structuring of business relationships, and investment in compliance infrastructure are the markers that distinguish operators who thrive from those who become defendants.
Proactive compliance evaluation and proper business model structuring are the strongest defenses available to operators and marketers in the advanced therapeutics space.
As this sector continues to grow, the enforcement attention will grow with it. The time to evaluate your exposure is before the government evaluates it for you. Understanding the regulatory landscape before launching or expanding marketing initiatives is not caution — it is the cost of operating responsibly in a high-stakes industry.
If you are a marketing professional, clinic operator, or healthcare consultant working in the GLP-1, peptide, or compounded therapeutics space — and you have questions about your federal regulatory exposure or need experienced counsel to evaluate your business model — call Aaron M. Cohen, 24 hours a day to get help.
Listen to Article
Part 1: Introduction
Overview of the regulatory landscape facing GLP-1, peptide, and compounded therapeutics marketing
Aaron M. Cohen
Principal Attorney
Aaron M. Cohen is a nationally recognized criminal defense attorney with over 30 years of experience representing individuals and entities in complex criminal investigations and prosecutions across the United States.
View Attorney Profile